|
Jim Wilson, MD, PhD
Founder, iECURE, Director, Gene Therapy Program, Rose H. Weiss Professor and Director, Orphan Disease Center, Professor of medicine and Pediatrics, Department of Medicine, Perelman School of Medicine
University of Pennsylvania
|
James M. Wilson, MD, PhD
Rose H. Weiss Professor and Director, Orphan Disease Center
Professor of Medicine and Pediatrics
Director, Gene Therapy Program
Perelman School of Medicine, University of Pennsylvania
Co-Founder and Scientific Advisor, Scout Bio
Co-Founder and Chief Scientific Advisor, Passage Bio
Co-Founder, G2 Bio
Co-Founder, Chief Scientific Officer, and Board Member of Institute for Life-Changing Medicine (ILCM)
Co-Founder, iECURE
James M. Wilson, MD, PhD, is a Professor in the Perelman School of Medicine at the University of Pennsylvania where he has led an effort to develop the field of gene therapy. His research career spanning over 40 years has focused on rare diseases and ways to treat them by gene therapy. Dr. Wilson has published over 600 papers and is named on over 200 patents worldwide. The Wilson lab identified a new type of vector based on novel isolates of adeno-associated viruses which have become best in class for gene therapy. There are currently more than 80 preclinical and over 40 clinical programs that use Dr. Wilson’s AAV vectors. More recently Dr. Wilson’s laboratory has focused on improved vectors for gene therapy and clinical applications of genome editing and mRNA therapy.
Rose H. Weiss Professor and Director, Orphan Disease Center
Professor of Medicine and Pediatrics
Director, Gene Therapy Program
Perelman School of Medicine, University of Pennsylvania
Co-Founder and Scientific Advisor, Scout Bio
Co-Founder and Chief Scientific Advisor, Passage Bio
Co-Founder, G2 Bio
Co-Founder, Chief Scientific Officer, and Board Member of Institute for Life-Changing Medicine (ILCM)
Co-Founder, iECURE
James M. Wilson, MD, PhD, is a Professor in the Perelman School of Medicine at the University of Pennsylvania where he has led an effort to develop the field of gene therapy. His research career spanning over 40 years has focused on rare diseases and ways to treat them by gene therapy. Dr. Wilson has published over 600 papers and is named on over 200 patents worldwide. The Wilson lab identified a new type of vector based on novel isolates of adeno-associated viruses which have become best in class for gene therapy. There are currently more than 80 preclinical and over 40 clinical programs that use Dr. Wilson’s AAV vectors. More recently Dr. Wilson’s laboratory has focused on improved vectors for gene therapy and clinical applications of genome editing and mRNA therapy.